Relx (LON:REL)‘s stock had its “hold” rating restated by Deutsche Bank in a research note issued to investors on Friday, ThisIsMoney.Co.Uk reports.
Other equities analysts have also issued reports about the company. Goldman Sachs Group upgraded Las Vegas Sands to a “buy” rating in a research report on Tuesday, June 11th. UBS Group set a $54.00 price target on Westlake Chemical and gave the stock a “sell” rating in a research report on Tuesday, July 2nd. Finally, JPMorgan Chase & Co. set a $195.00 price target on bluebird bio and gave the stock a “buy” rating in a research report on Friday, May 17th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of GBX 1,821.50 ($23.80).
REL opened at GBX 1,939.50 ($25.34) on Friday. The stock’s 50 day moving average is GBX 1,898.85. The company has a current ratio of 0.44, a quick ratio of 0.36 and a debt-to-equity ratio of 270.50. Relx has a 1 year low of GBX 1,466.50 ($19.16) and a 1 year high of GBX 1,982.50 ($25.90). The company has a market cap of $37.78 billion and a price-to-earnings ratio of 27.16.
Relx Company Profile
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Featured Story: Golden Cross
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.